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Abstract
Background: Autoimmune hepatitis causes chronic hepatitis and often leads to cirrhosis and death without
treatment. We wanted to see if having access to primary care or insurance prior to diagnosis is associated with
better outcomes for patients in an urban, public hospital with mostly socioeconomically disadvantaged Hispanic
patients.
Methods: We did a retrospective study at our institution. Kaplan Meier survival analysis was done looking at
transplant-free overall survival for patients diagnosed at our institution. The log-rank test was done to compare
survival between patients with and without prior access to primary care, and between patients with and without
insurance at diagnosis.
Results: Overall 5- and 10-year transplant-free overall survival was 91 % (95 % CI, 83-100 %) and 75 % (95 % CI,
50-99 %), respectively. Patients with primary care prior to diagnosis had significantly better transplant-free overall
survival than those without (log rank test p = 0.019). Patients with primary care also had better clinical markers at
diagnosis. Having insurance at diagnosis was not associated with better outcomes.
Conclusions: Outcomes of autoimmune hepatitis are poor in our setting but access to primary care prior to
diagnosis was associated with better outcomes. This is likely due to the important role that primary care plays in
detecting disease and initiating treatment earlier. With the expansion of access to healthcare that the Affordable
Care Act provides, future patients are likely to do better with even rare diseases like autoimmune hepatitis.
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Background
Autoimmune hepatitis (AIH) is an inflammatory condition
of the liver that can cause chronic hepatitis and cirrhosis.
Without treatment, 10-year survival rates are less than
30 %, while with treatment, the 10-year transplant-free
survival rate ranges from 85-95 % [1–4]. This data, how-
ever, describes mostly non-Hispanic white patients with
insurance, in quaternary care settings. Data on outcomes
in patients of other ethnicities, especially Hispanics, and in
safety-net or low socioeconomic settings are lacking.
In this report, we describe our experience with auto-
immune hepatitis in a large urban public hospital in Los
Angeles, California that serves a mostly indigent, Hispanic
population with higher rates of poverty and lower access
to healthcare compared to the county average. At diagno-
sis with autoimmune hepatitis, some patients are already
established within the county primary care network while
others are presenting to the county health care system for
the first time. Likewise, some patients already have access
to some form of insurance (e.g. Medicaid, county-based
funding) while others do not. Our aim was to see if having
primary care or insurance at diagnosis was associated with
better outcomes.
Methods
This study was conducted in a 350-bed county-run hospital
that serves a mostly indigent population, a substantial por-
tion of which cannot qualify for liver transplant because of
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undocumented immigration status. The hospital’s inpatient
discharges are 50 % covered by Medicaid and 20 %
covered by county funding. As a surrogate indicator of
patients’ socioeconomic background, we used patients’
home zip codes to determine, by geographical area,
median household income, proportion living under the
federal poverty line [5], and whether the patient lived
in an area designated as a “Medically Underserved
Area” (MUA) or “Health Professional Shortage Area”
(HPSA) [6]. These were included in patients’ baseline
characteristic data.
We performed an anonymous retrospective review of
patients newly diagnosed with autoimmune hepatitis and
managed at our institution between 2001 and 2013. This
study was exempt from obtaining consent to access pa-
tient data. These patients presented to the gastroenter-
ology service either through referrals from primary care
physicians within our county network of clinics or by
presenting to our emergency room and being admitted.
We queried “Autoimmune Hepatitis” in our pathology
department’s database and “Autoimmune Hepatitis” in
our hospital’s registry of patients’ ICD-9 diagnoses. Of the
patients found in this query, we included patients whose
clinical documentation indicated a gastroenterologist’s
diagnosis of autoimmune hepatitis supported by clinical
findings (liver biopsy, biochemical data, history, etc.)
consistent with the revised International Autoimmune
Hepatitis Group (IAHG) clinical criteria [7]. Liver biopsies
were evaluated by pathologists at our facility and findings
of lymphoplasmacytic infiltration or interface hepatitis
were considered consistent with AIH. Patients were diag-
nosed with cirrhosis based on findings on liver biopsy. Ex-
clusion criteria included lack of liver biopsy, age less than
18, diagnosis at another facility, incomplete records, and
alternative/concurrent diagnosis of liver disease (e.g. viral
hepatitis or overlap syndrome).
Demographic data was obtained from the central hospital
database. Ethnicities were self-reported: non-Hispanic white
(i.e. Caucasian), Hispanics, African Americans and Asian/
Pacific-Islander (i.e. Asians).
Our institution’s gastroenterologists made treatment
decisions, including those regarding medication dosing.
Patients with AIH were initially treated with prednisone
at an oral dose of 30–60 mg daily or methylprednisolone
at an intravenous dose of 60 mg daily. Azathioprine or
6-mercaptopurine was either added at a dose of 50–75 mg
to prednisone initially or if biochemical and clinical re-
sponses were noted within 4–8 weeks. Once response
was noted, prednisone was gradually reduced and tapered
off within 1 year. Moreover, liver function tests were
performed every 1- to 3- months on maintenance doses
of prednisone and/or an immunomodulating agent. Re-
sponse and remission were defined per clinicians’ sub-
jective assessment of biochemical and clinical data.
We recorded two sets of outcomes: 1) a combined end-
point of death and/or liver transplant and 2) a combined
endpoint of death, liver transplant, or being lost to follow-
up. Follow-up time was defined as time from presentation
to a primary endpoint or time of last follow-up. Being lost
to follow up was defined as the absence of a clinic visit at
any of our hospital’s departments or any laboratory evalu-
ation for 18 months or more after their last clinic visit or
laboratory study.
We compared patients with and without primary care
at diagnosis for differences in outcomes. We also com-
pared patients with and without insurance at diagnosis
for differences in outcomes. Patients were included in the
group with primary care if they had at least six months
of Internal Medicine or Family Medicine visits at a Los
Angeles Department of Health Services facility prior to
diagnosis with AIH. Patients were included in the group
with insurance if they had Medicaid, Medicare, private
insurance, or a form of Los Angeles County funding (for
patients who do not qualify for Medicaid) at the time of
diagnosis.
All statistical analyses were performed using the
SPSS 18 (SPSS Inc. Released 2009. PASW Statistics for
Macintosh, Version 18.0. Chicago: SPSS Inc). The chi-
squared test and Fisher’s exact test were used to make
comparisons of categorical data, the student’s t-test
was used to compare parametric continuous data, and
the Mann–Whitney U test was used to make comparisons
of nonparametric continuous data. Baseline characteristic
data was compared between groups stratified by having
primary care and by having insurance. Log-rank testing
was done to compare the survival of two groups. Overall
transplant-free survival and overall transplant-and-lost-to-
follow-up-free survival was analyzed using the Kaplan-
Meier method and the log-rank test was used to compare
survival between groups. A P-value ≤0.05 was considered
statistically significant.
Ethical approval and consent
This study was deemed exempted by the John Wolff
IRB of the Los Angeles Biomedical Research Institute
at Harbor-UCLA Medical Center.
Availability of supporting data
The data set supporting the results of this article is avail-
able in the Labarchives respository [http://www.labarchi-
ves.com] associated with the DOI 10.6070/H4G44N84.
Results
One hundred and fifty patients were identified. All patients
had an assessment of clinical data included symptoms
at presentation, concurrent liver diseases, laboratory
data (e.g. liver function panel, ANA, smooth muscle
antibody) and cirrhosis. Model for End-Stage Liver Disease
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(MELD) scores were calculated for patients with cirrhosis
using clinical data from presentation to represent severity
of liver disease at that time [8]. Sixty-seven were excluded
for the following reasons: 15 were excluded because
they lacked a liver biopsy, 5 were diagnosed at another
facility, 2 had incomplete records, 4 had primary biliary
cholangitis (PBC), 1 had alcoholic hepatitis, 1 had an
alternative unknown diagnosis, 22 had AIH with overlap
syndrome (21 with PBC and 1 with primary sclerosing
cholangitis), and 7 had viral hepatitis. Eighty-three patients
met IAHG criteria for autoimmune hepatitis and were
included for final analysis.
Table 1 Baseline characteristics
Full cohort Without PCP With PCP p
n 83 57 26
Female (%) 70 (84) 47 23 0.746
Ethnicity (Hispanic:Asian:White) (%) 70:8:5 (84:10:6) 46:7:1 24:1:1
Median age at presentation (yr) (IQR) 48 (41–57) 48 (40–59) 46 (41–55) 0.776
Fundinga (%) 48 (58) 29 (51) 19 (73) 0.057
Medicare 4 3 1
Medicaid 22 15 7
County Funding 22 9 13
MUA/HPSAb (%) 42 (51) 31 11 0.307
Poverty Rate of Zip Code (IQR) 22.1 (15.6-26.2) 24.5 (15.6-29) 19.4 (12.9- 23.8) 0.267
Median Income of Zip Code (IQR) 43364 (38903–55784) 43364 (35836–53738) 45556 (42712–57586) 0.160
Median follow-up (mo) (IQR) 21 (7.5-65.7) 15 (6.5-61) 44 (11–89) 0.209
Lost to follow-up (%) 26 (31) 23 (40) 3 (12) 0.010
Presented with Decompensation (%) 6 (7) 6 (11) 0 (0) 0.170
Acute Disease (Symptoms < 2 week) (%) 37 (45) 26 (46) 11 (42) 0.779
Cirrhosis at presentation (%) 32 (39) 26 (46) 6 (23) 0.05
Any decompensation (%) 26 (31) 21 (37) 5 (19) 0.109
ANA >1:40 (%) 59 (71) 37 (65) 22 (85) 0.075
SMA (%) 58 (70) 38 (67) 20 (77) 0.557
LKM (60 checked) (%) 4 (5) 3 (5) 1 (4) 0.762
ANA or SMA (%) 75 (90) 50 (88) 25 (96) 0.425
Other autoimmune disease (e.g. lupus, rheumatoid arthritis, etc.) (%) 23 (28) 12 (21) 11 (42) 0.048
AST (IQR) 429 (157–1248) 487 (136–1329) 418 (168–1074) 0.871
ALT (IQR) 657 (152–1450) 700 (179–1564) 427 (143–942) 0.525
Bilirubin (IQR) 5.2 (1.5-21.2) 11.9 (2.1-22.9) 2.1 (0.7-10.3) 0.040
Albumin (IQR) 2.5 (1.8-3.2) 2.4 (1.8-2.8) 3.1 (2.1-3.5) 0.019
INR (IQR) 1.3 (1.1-1.8) 1.4 (1.1-2.0) 1.1 (1.0-1.3) 0.007
Platelets (IQR) 160 (90–120) 146 (84–202) 174 (114–219) 0.009
IgG (IQR) 1830 (1500–2350) 1820 (1475–2530) 1850 (1500–2170) 0.871
MELD Score (in patients with cirrhosis) (IQR) 17.1 (11.5-24.0) 17.9 (13.0-24.5) 13.9 (9.2-19.4) 0.244
Flu-like symptoms (%) 22 (27) 15 (26) 7 (27) 0.954
Abdominal pain (%) 36 (43) 24 (42) 12 (46) 0.730
Jaundice (%) 54 (65) 41 (72) 13 (50) 0.052
Pruritis (%) 6 (7) 4 (7) 1 (4) 0.660
GI bleed (%) 6 (7) 6 (11) 0 (0) 0.170
Ascites (%) 23 (28) 20 (35) 3 (11) 0.034
Encephalopathy (%) 10 (12) 8 (14) 2 (8) 0.494
aFunding was defined as patient having Medicaid, Medicare, Private Insurance, or a County form of insurance
bMUA =Medically Underserved Area, HPSA = Health Professional Shortage Area
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Baseline characteristic data for the entire cohort are
described in Table 1. 84 % were female and 84 % were
Hispanic, 10 % Asian, and 6 % White. The median esti-
mated household income was $43,364 in our patients’
home zip codes, compared to a county average of $56,241;
the median proportion of the population living under the
federal poverty line was 22 % in our patients’ zip codes,
compared to the county rate of 17 % [9]. 51 % of our
patients were from areas designated MUA/HPSA. 39 %
presented with cirrhosis, and 7 % presented with de-
compensated cirrhosis. There were no asymptomatic
patients. 49 % scored a definite diagnosis and 51 %
scored a probable diagnosis. Sixty-seven patients were
treated. Median follow-up time was 21 months. There
were 18 deaths and 3 transplants at the time of data
collection. 31 % were lost to follow-up. Overall 5- and
10-year transplant-free overall survival was 91 % (95 %
CI, 83-100 %) and 75 % (95 % CI, 50-99 %), respectively
(Fig. 1). Because a large portion of the cohort was lost
to follow-up, we did an additional two-tailed sensitivity
analysis for patients lost to follow-up, in which the
upper limit assumed patients lost to follow-up survived
without transplant and the lower limit assumed patients
lost to follow-up died or had a liver transplant; in this case,
5- and 10- year survival rates for the lower limit were
50 % (95 % CI, 62-37 %) and 18 % (95 % CI, 32-4 %),
respectively, and for the upper limit, 85 % (95 % CI, 93-
77 %) and 81 % (95 % CI, 91-73 %), respectively.
There was a significant difference in transplant-free
survival between patients who had primary care compared
to those without (log rank test p = 0.019, Fig. 2). 5- and 10-
year transplant-free survival rates for patients with primary
Fig. 1 Overall survival
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care were 89 % (95 % CI, 100-73 %) and 45 % (95 % CI,
100-0 %), respectively, and for patients without primary
care 5- and 10- year rates were 68 % (95 % CI, 84-53 %)
and 28 % (95 % CI, 55-1 %), respectively. There were no
significant differences in baseline characteristics or survival
between patients with and without insurance at the
time of diagnosis.
Patients without prior primary care access at diagno-
sis were more likely to be lost to follow-up, and had
significantly worse markers of liver disease such as cir-
rhosis on biopsy, platelets, INR, albumin, bilirubin, and
ascites (Table 2). Patients without prior primary care
access were also much less likely to get treatment.
Discussion
Our report shows that in a unique cohort of AIH pa-
tients who are predominantly Hispanic treated at an
urban safety-net hospital, lack of primary care was as-
sociated with worse disease characteristics at diagnosis
and worse outcomes. Patients lacking primary care, at
diagnosis, had worse rates cirrhosis and ascites, and worse
laboratory markers of liver dysfunction (e.g., lower albu-
min, lower platelets, higher bilirubin). These patients also
had higher rates of death and liver transplant.
AIH is a disease that often has a long subclinical course
that leads to development of end-stage liver disease. Given
this, we hypothesized that patients with regular primary
care will likely have their disease diagnosed in earlier stages
and have better outcomes than those without primary care.
Our results support this supposition. Interestingly, having
insurance was not a significant factor associated with better
outcomes, suggesting that patients need to actually see their
physicians to benefit. In addition, AIH is a disease with
good prognosis when treated, but significantly fewer
Fig. 2 Comparison of survival by primary care access
Kim et al. BMC Gastroenterology  (2015) 15:91 Page 5 of 7
patients lacking primary care in our cohort were treated
due to their having Childs B or C cirrhosis or other acute
illnesses such as sepsis.
Patients in our cohort had important factors that made
them less likely to have access to primary care. They lived
in areas with lower incomes and higher rates of poverty
and shortages of doctors compared to the county average
[9] and they also had much lower rates of insurance cover-
age compared to the national average [10]. Hispanics, of
which our cohort was mostly composed, are disproportion-
ately likely to be of low socioeconomic status, lack access to
health care and use safety net hospitals [11].
With the implementation of the Affordable Care Act,
we hope to see expanded primary care access for the
previously uninsured—particularly for those living in
poverty, and for Hispanics. Through many encounters
over time, improved management of treatable chronic
illnesses with high morbidity and mortality, like AIH,
can be achieved. Ensuring good follow up will be essential
for producing good outcomes, but in safety net settings,
where many patients with poor access to health care are
treated, this has been challenging [12]. Active changes
are being made in our own institution, such as patient-
centered medical homes, electronic specialty consultation
from primary care clinics, and a new electronic medical
record, with the hope that these improvements may
improve this problem. This should help primary care
physicians and specialists better coordinate care and be
more vigilant against losing patients due to systemic issues.
Our study had some important limitations. Compar-
isons between ethnicities were not possible because of
the cohort’s small size. Given that AIH is a relatively
rare disease, large, prospective studies are likely to be
difficult, especially in the safety-net setting. Its retro-
spective nature makes it vulnerable to bias. Endpoints
such as remission and relapse were subjectively defined
by clinicians and sometimes did not strictly adhere to
AASLD-defined criteria, and this increases risk of bias
as well.
Conclusion
In summary, this report shows that access to primary
care prior to the diagnosis of AIH in a safety net hospital
setting with mostly Hispanic patients is associated with
better outcomes, while merely having insurance at presen-
tation is not associated with any difference in outcomes.
Patients who lacked primary care access also presented
with worse liver disease.
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Table 2 Comparison of patients with and without primary care follow-up
Full cohort Without PCa With PCa p
N (%) N (%) N (%)
n 83 57 26
Treated 67 (81) 41 (72) 26 (100) 0.002
Not treated due to decompensation/Childs B or C disease 6 6 0
Not treated because "No indication" according to clinician 2 2 0
Not treated because LFTs or liver enzymes either were normal,
insignificantly elevated, or resolved on own
5 5 0
Unclear why not treated 2 2 0
Patient to follow up with PC physician 1 1 0
Remission 43 (52) 28 (49) 15 (58) 0.469
Noncompliance 10 (12) 6 (11) 4 (15) 1.000
Steroid median dose 40 (IQR 40–60) 40 (IQR 40–60) 40 (IQR 40–55) 0.535
Median time corticosteroids (months) 12 (14.5) 12 (IQR 5–23) 15 (IQR 12–28) 0.115
Median time to ALT normalization (months) 1.4 (IQR 0.8-3.3) 1.3 (IQR 0.8-3.7) 1.6 (IQR 0.6-2.9) 0.504
Relapses 23 (27) 12 (21) 11 (42) 0.380
aPC = Primary Care (Defined as 6 months or greater of Internal Medicine and Family Medicine visit physician follow-up)
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